Abstract： Objective： To explore the mechanism of Alismatis Rhizoma in treating atherosclerosis by network pharmacology and molecular docking technology. Methods： The active components and related targets of Alismatis Rhizoma were screened through Traditional Chinese Medicine systematic pharmacology database and analysis platform (TCMSP) and Swiss Target Prediction database. Use Gene Cards，OMIM， TTD and other databases to search for atherosclerotic disease related targets， finally get the common target of Alismatis Rhizoma and atherosclerosis， and carry out GO biological process and KEGG pathway enrichment analysis ， and use AutoDock Vina software for molecular docking verification. Results ： The 10 main active components and 327 potential targets of Alismatis Rhizoma may affect lipid metabolism， steroid metabolism and inflammatory response by regulating phosphatidylinositol- 3- kinase (PI3K)， interleukin(IL)， epidermal growth factor and other related proteins as well as PI3K- Akt， IL- 17， AGE-RAGE and other signal pathways. The results of molecular docking verification suggest that Alismatrol B， Alismatrol C， and Alismatrol A plus core targets have more significant protein binding activity. Conclusion： Alismatis Rhizoma plays an anti- atherosclerotic role by regulating lipid metabolism， antiinflammation， anti- oxidative stress，and regulating endothelial function，providing pharmacological basis for clinical application.